Association between glucagon-like peptide-1 receptor agonist therapy and respiratory illness in patients with type 2 diabetes: a retrospective observational cohort study
8.0
来源：
Nature
关键字：
ML brain science
发布时间：
2025-10-14 03:36
摘要：
A retrospective cohort study involving over 3 million patients with type 2 diabetes mellitus (T2DM) found that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) significantly reduce the risk of lung cancer and respiratory illnesses compared to dipeptidyl peptidase-4 inhibitors (DPP4is). The study indicates that GLP-1 RAs may offer protective benefits beyond glycemic control, warranting further investigation into their mechanisms and potential applications in oncology and respiratory health.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0
business_impact
1.0
scientific_rigor
1.5
timeliness_innovation
1.5
investment_perspective
2.5
market_value_relevance
1.0
team_institution_background
0.5
technical_barrier_competition
0.5
关键证据
GLP-1 RA users had a significantly lower risk of lung cancer than did DPP4i users (HR 0.86).
The study involved a large cohort of over 3 million patients, enhancing the reliability of the findings.
GLP-1 RAs may lower the risks of lung cancer, pulmonary fibrosis, and respiratory infections.
真实性检查
否
AI评分总结
A retrospective cohort study involving over 3 million patients with type 2 diabetes mellitus (T2DM) found that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) significantly reduce the risk of lung cancer and respiratory illnesses compared to dipeptidyl peptidase-4 inhibitors (DPP4is). The study indicates that GLP-1 RAs may offer protective benefits beyond glycemic control, warranting further investigation into their mechanisms and potential applications in oncology and respiratory health.